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Background: Baker’s/brewer’s yeast, Saccharomyces cerevisiae, has been used as an alternative to antibiotic growth
promoters to improve growth performance in animals. In humans, Saccharomyces cerevisiae is among the most
commonly detected fungi in fecal samples and likely originates from food. Recently, an association between anti-
Saccharomyces cerevisiae antibodies (ASCA) and obesity in humans was suggested, but the cause of the elevated
ASCA levels is not clear. Our aim was to study ASCA in morbidly obese subjects and explore potential associations
with anthropometrics, diet, co-morbidities and biomarkers of inflammation and gut permeability.
Methods: Subjects with morbid obesity referred to a specialized hospital unit were included. Diet and clinical data
were recorded with self-administered questionnaires. Main dietary sources of baker’s/brewer’s yeast (e.g. bread and
beer) were used as a proxy for the intake of yeast. Laboratory analyses included ASCA, serum zonulin (reflecting gut
permeability), C-reactive protein and a routine haematological and biochemical screening.
Results: One-hundred-and-forty subjects; 109 (78%) female, 98 with dietary records, mean age 43 years and BMI
42 kg/m2 were included. The number of ASCA positive subjects was 31 (22%) for IgG, 4 (2.9%) for IgA and 3 (2.1%)
for IgM. Age, body fat mass and C-reactive protein were significantly higher in IgG-positive compared to IgG-
negative subjects (P < 0.05). A borderline significant association was found between elevated zonulin and ASCA
IgG-positivity (P = 0.06). No association was found between yeast-containing food and ASCA IgG-positivity, or
between yeast-containing food and fat mass.
Conclusions: The findings indicate that ASCA IgG-positivity may be linked to the generalized inflammation
commonly seen with increased adiposity, but not to dietary yeast intake. Other potential causes for the raised ASCA
IgG concentrations, such as genetic predisposition, deviations in the gut microbiota and cross-reactivity of ASCA with
other antigens, were not explored.
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In animal husbandry, cultures of Saccharomyces cerevi-
siae (also known as baker’s and brewer’s yeast) and their
cell wall components have appeared as promising alter-
natives to Antibiotic Growth Promoters in order to im-
prove growth performance, feed intake and feed
efficiency [1, 2]. Speculatively, similar effects could be
present in humans. In a study from 2015, Salamati et al.
investigated associations between anti-Saccharomyces
cerevisiae antibodies (ASCA) IgG and IgA and obesity
[1]. In this study, ASCA levels were higher in morbidly
obese than in normal weight subjects, and there was a
correlation between ASCA and BMI [1]. The cause of
the elevated ASCA levels is however not clear.
Saccharomyces cerevisiae is among the most com-
monly detected fungi in human fecal samples and it pre-
sumably originates from food [3]. In human diet, bread
is one of the main dietary sources of this yeast (baker’s
yeast), along with beer (brewer’s yeast). The scientific lit-
erature does however not support a relationship between
bread consumption and obesity, although consumption
of white bread, as opposed to whole grain bread, might
be associated with excess abdominal fat and impaired
weight loss [4]. To our knowledge, an association be-
tween ASCA and yeast-containing food in relation to
obesity remains to be explored.
Saccharomyces cerevisiae also has the ability to grow
at body temperature and to respond to the gut environ-
ment, suggesting that it may play a role in gut microbial
ecology [3]. A growing body of evidence suggests that
deviations in the gut microbiota and increased intestinal
permeability are associated with obesity and the meta-
bolic inflammation that may accompany excess adiposity
[5]. A recent recognition is that specific anti-microbial
antibodies may as well be raised in obesity and associ-
ated co-morbidities, such as diabetes and glucose in-
tolerance [6]. Increased gut permeability, with the
potential translocation of Saccharomyces cerevisiae or
related luminal antigens, could thus be another cause of
elevated ASCA concentrations in obesity.
The aims of the present paper were to study ASCA in
subjects with morbid obesity in a larger study than the
previously published study by Salamati et al. [1], and to
study associations between ASCA and dietary intake,
obesity-related co-morbidities and biomarkers of inflam-
mation and gut permeability.
Methods
The present study used data from a cross-sectional study
at Innlandet Hospital Trust, Gjøvik, Norway. Patients
referred for morbid obesity (BMI ≥ 40 kg/m2 or
BMI ≥ 35 kg/m2 with obesity related complications (e.g.
diabetes, hypertension, sleep apnoea, musculoskeletal
problems) from December 2012 to September 2014 wereasked to participate in the study. The patients were eval-
uated for bariatric surgery or non-surgical treatment of
obesity. The patients had not started the weight redu-
cing intervention at the time of study inclusion. The
study used a large range of questionnaire data collected
at the time of inclusion, with a case report form and a
food frequency questionnaire (FFQ). Supplementary in-
formation was collected from the patient records. For
the present sub-study, patients with organic gastrointes-
tinal disorder, former major gastrointestinal surgery, un-
satisfactory filled in case-report form or lacking blood
samples for the biobank were excluded.
Case report form
Included age, gender, height, weight, education, marital
status, occupation, employment, physical activity, smok-
ing, alcohol consumption, perception of overall state of
health, musculoskeletal complaints, mental distress
(Hopkins Symptom Checklist 10 (HSCL-10): a score
above 1.85 indicates mental distress (range: 1–4)) [7]
and other co-morbidities. All these questions have been
validated and used in accordance with The Norwegian
Institute of Public Health’s population based surveys.
Additionally, Irritable bowel syndrome (classified ac-
cording to the Rome III criteria) [8], perceived food in-
tolerance in association with gastrointestinal symptoms
and the following health scores were also included in the
case-report form: well-being (WHO-5; score: 0–100) [9],
sense of humour (SHQ-6; score: 6–24) [10], fatigue
(score: 1–7) [11], sleepiness (Epworth; score: 0–24) [12]
and self-esteem (Rosenberg; score: 10–40) [13]. In case
of missing data within a scoring algorithm, the data were
treated as follows: If a patient answered less than 50% of
the questions, the health score was evaluated as blank/
missing (Rosenberg: 1 patient. Humor: 1 patient),
otherwise the missing values (0%-0.57% for each tool)
were assigned the least pathological option among the
alternatives.
Diet
The patients were asked to recall their habitual diet
during the last year by answering a FFQ, prepared and
validated by the University of Oslo [14, 15]. Daily intake
of food, nutrients and energy was calculated by
Department of Nutrition at the University of Oslo by
their in-house calculation program (KBS, version 7.3,
food database AE-14). The food composition database
in the calculation program is based on the official
Norwegian food composition table from 2016 [16]
and is supplemented with additional food items. In-
takes from dietary supplements were included in the
calculations. Bread, buns and other baked goods that
typically contain (baker’s) yeast, and beer (brewer’s
yeast), were used as a proxy for the intake of yeast.
Fig. 1 Inclusion diagram
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summarizing the intakes of these food items for each
patient.
Laboratory analyses
The patients were asked to fast the night before the
blood draw. Serum and EDTA plasma were then col-
lected and immediately analysed or stored at −80 °C for
later analysis. ASCA; IgG, IgA and IgM against Saccha-
romyces cerevisiae mannan, were determined with an
Enzymatic Linked Immunosorbant Assay according to
the manufacturer’s instructions (IgG and IgA: DRG
International, Inc., and IgM: BIOGEMA Košice). A posi-
tive test result was defined as ≥10 U/mL for IgG and
IgA and ≥33 U/mL for IgM, as suggested by the manu-
facturers. The ASCA analyses were performed by Vitas
AS, Oslo, Norway. Serum zonulin, a marker of intestinal
permeability (reference range < 48 ng/mL) was mea-
sured by Lab 1, Sandvika, Norway (SYNLAB group;
SYNLAB International GmbH) using an Enzymatic
Immunosorbant Assay. Serum C-reactive protein (CRP)
was analysed as part of a routine haematological and
biochemical screening, including a total number of 44
parameters (e.g. red blood cell indices, haemoglobin,
iron status parameters, leukocytes, thrombocytes,
markers of kidney and liver function, thyroid hormones,
blood lipids, glucose, HBA1C, electrolytes and vitamins).
Statistical analyses
Data analyses were performed with IBM SPSS Statistics
for Windows, Version 23 (IBM Corp., Armonk, N.Y.,
USA). Associations between variables were tested with
logistic and linear regression models. Adjustments were
made for age, gender and BMI, as these were considered
clinically relevant co-variates. If another anthropometri-
cal variable was included in the model (i.e. height,
weight, fat mass or fat percentage) adjustment for BMI
was not performed. Ordinal independent variables with-
out pre-defined categories (e.g. health indexes with a
lower and upper total score) were treated as continuous
variables in the model. Interactions were tested by adding
an interaction term to the regression model. Significance
level was set at a P-value <0.05. The 95% confidence inter-
vals (CI) for the prevalence of positive ASCA IgG, IgA
and IgM levels were obtained using StatXact 10 (Cytel
Software Corporation, Cambridge MA, USA).
Post-hoc tests
Due to initial findings from association analyses be-
tween ASCA and anthropometrical data, we included
an estimate of body fat percentage using the formula
developed by Gallagher et al. [17], and estimated body fat
mass in kg (estimated body fat percentage [17] * weight
in kg/100).Results
Figure 1 shows the number of included and excluded
patients. Of 159 included patients, 140 patients
(male/female 31/109, mean age 43.1 years) were avail-
able for the analyses. Of these, 98 had completed the
FFQ. Table 1 gives the patients’ characteristics.
Thirty-one patients (22%; 95% CI: 16 to 30%), 4 pa-
tients (2.9%; 95% CI: 0.8 to 7.1%) and 3 patients (2.1%;
95% CI: 0.4 to 6.1%) had ASCA IgG, IgA and IgM levels
above the respective reference values. Because of the
high frequency of IgG-positivity, further analyses were
restricted to comparisons between patients with ASCA
IgG above and below 10 U/mL. The results from these
analyses showed significant and direct associations be-
tween ASCA IgG-positivity and age, height, weight, body
fat mass and serum CRP respectively (Tables 2 and 3).
Elevated zonulin concentrations (≥ 48 ng/ml) were more
frequently detected in the IgG-positive compared to the
IgG-negative group, but the difference did not reach
statistical significance (Table 3). Moreover, using linear
regression, significant positive associations were found
between body fat mass (independent variable) and CRP;
B = 0.14 (0.01–0.28), P = 0.04, and between zonulin di-
chotomized at 48 ng/ml (independent variable) and
CRP; B = 3.28 (1.10–5.46), P < 0.01, but not between
zonulin dichotomized (independent variable) and body
fat mass; B = 0.07 (−2.76–2.91), P = 0.96. No associa-
tions were found between ASCA IgG-positivity and the
dietary intake data, neither with respect to food groups,
nor nutrients. In particular, no associations were found
between ASCA IgG and yeast-containing food, energy-
yielding nutrients or total energy intake (Table 2).
Table 1 Demographical and clinical data for the study
population a
All patients, n = 140 b
Age, years 43.1 (8.7)
Gender (male/female) 31 (22%)/109 (78%)
Ethnic Nordic background 138 (99%)
Height, cm 169 (149–197)
Weight, kg 120 (90–192)
BMI, kg/m2 41.6 (35–55)
Body fat, percentage of body weight 46.8 (31–51)
Body fat mass, kg 54.1 (39–81)
Smoking (never/former/current) 55 (39%)/60 (43%)/25 (18%)
Previous or present co-morbidity
Diabetes mellitus 26 (19%)
Polycystic ovary syndrome 7 (6.4%)
Hypertension 46 (33%)
Angina pectoris 1 (0.7%)






Irritable bowel syndrome (Rome III) 35 (26%)
Chronic obstructive pulmonary disease 3 (2.1%)
Asthma 34 (24%)
Hay fever 19 (14%)
Osteoporosis 0 (0%)
Asked for help for psychological problems 28 (20%)
Mental distress (HSCL-10 score > 1.85) 34 (24%)
aData are expressed as mean (SD), median (min-max) and n (%)
bAll data are based on n = 140 with the following exceptions: 1) Irritable bowel
syndrome: n = 135. 2) Polycystic ovary syndrome; n = 109 (females only)
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total intake of yeast-containing food (independent vari-
able) and the obesity indices BMI (B = 0.003, P = 0.38),
body fat percentage (B = 0.001, P = 0.60) or body fat
mass (B = 0.006, P = 0.41). Also, no interactions were
found between ASCA IgG (above and below 10 U/ml)
and the total intake of yeast-containing food with re-
spect to these anthropometrical outcomes (all P-values
>0.05). The two groups (ASCA IgG-positive versus
ASCA IgG-negative) were otherwise similar in terms of
physical activity, smoking, alcohol consumption, co-
morbidities and other clinical and biochemical charac-
teristics, with the following exceptions: HSCL-10
score > 1.85 (indicating mental distress) was significantly
more prevalent (Table 2), and serum albumin and serum
protein were significantly higher (Table 3) among theIgG-positive compared to the IgG-negative subjects.
Blood mean corpuscular volume and mean corpuscular
hemoglobin were significantly lower among the IgG-
positive compared to the IgG-negative subjects, whereas
no significant differences were found in related parame-
ters (e.g. hemoglobin and ferritin) between the two
groups (Table 3). The variables assumed to be of main
clinical interest and all statistically significant variables
are displayed in Tables 2 and 3.
Discussion
In the present study, including 140 patients, 22% had a
positive ASCA IgG test result. This frequency of ASCA
positivity in subjects with morbid obesity was at least of
the same order of magnitude as the previous publication
by Salamati et al. [1]. Our study did however not show
an association between ASCA and BMI. This might have
been due to the fact that our study included subjects
with morbid obesity only, limiting interpretations of re-
sults to this BMI range. On the other hand, an associ-
ation was detected between ASCA IgG-positivity and
body fat mass, suggesting that in a population of sub-
jects with morbid obesity, total amount of body fat is a
better predictor of ASCA than the relative amount of
body fat.
The findings of a relationship between ASCA and adi-
posity in humans are interesting considering the use of
Saccharomyces cerevisiae as a growth promoter in the
animal husbandry [1, 2]. Consumption of the main diet-
ary sources of baker’s/brewer’s yeast was however not
reflected by the plasma levels of ASCA IgG in our study,
indicating that ASCA IgG formation was unrelated to
yeast intake. Additionally, we did not find any associ-
ation between the total intake of these yeast-containing
foods and the anthropometrical indices BMI, body fat
mass or body fat percentage. This finding was independ-
ent of ASCA status, suggesting that effect modification
was unlikely. In all, these results do not support a causal
relationship between the consumption of baker’s/
brewer’s yeast and obesity in humans.
The amount and type of yeast in the gut may also de-
pend on the nutrient availability within the gut. A study
which reported associations between nutrients and the
presence of fungal populations in fecal samples did how-
ever not find any relationship between Saccharomyces
and the nutrient composition of the diet, either recent
or long term diet [18]. In the present study, there were
no associations between ASCA IgG and either energy
yielding nutrients or total energy intake.
In addition to the association between ASCA IgG and
body fat mass, our study showed an association between
ASCA IgG positivity and serum CRP. Obesity is associ-
ated with a state of low-grade inflammation, including
increments in serum CRP [19]. There is also some
Table 2 Clinical and dietary data; comparing ASCA IgG ≥ 10 U/mL to IgG < 10 U/mL a
IgG ≥ 10 U/mL n IgG < 10 U/mL n Adjusted for age, gender
and BMI b
P-value
Odds Ratio (95% CI)
Age, years 45.3 (7.9) 31 42.5 (8.8) 109 1.06 (1.00–1.11) 0.04 *
Gender (male/female) 9 (29%)/22 (71%) 31 22 (20%)/87 (80%) 109 1.29 (0.49–3.36) 0.61
Height, cm 172 (161–197) 31 168 (149–192) 109 1.09 (1.01–1.16) 0.02 c, *
Weight, kg 128 (95–183) 31 118 (90–192) 109 1.04 (1.01–1.07) <0.01 c, *
BMI, kg/m2 42.8 (3.9) 31 41.9 (3.8) 109 1.10 (0.98–1.24) 0.10
Body fat, percentage of body weight 48 (33–50) 31 47 (31–51) 109 1.22 (0.94–1.58) 0.14 c
Body fat mass, kg 59 (43–75) 31 53 (39–81) 109 1.07 (1.02–1.13) 0.01 c, *
Dietary intake
Bread, g 148 (24–267) 23 174 (48–444) 75 1.00 (0.99–1.00) 0.39
Beer, g 0 (0–180) 23 0 (0–140) 75 1.01 (0.99–1.02) 0.35
Bread, buns and other baked goods + beer, g 172 (24–387) 23 187 (53–1060) 75 1.00 (0.99–1.00) 0.39
Energy, kJ 9293 (5100–20,111) 23 9737 (4830–21,816) 75 1.00 (1.00–1.00) 0.58
Carbohydrates, g 251 (79–475) 23 247 (94–903) 75 1.00 (0.99–1.00) 0.60
Proteins, g 109 (64–177) 23 108 (43–213) 75 1.00 (0.99–1.02) 0.99
Fats, g 82 (27–231) 23 93 (38–283) 75 1.00 (0.99–1.01) 0.61
Alcohol, g 0.6 (0–10) 23 1.3 (0–21) 75 0.93 (0.79–1.08) 0.33
Physical activity (light) d 31 109
< 1 h/week (reference) 7 (23%) 30 (28%)
1–2 h/week 13 (42%) 43 (39%) 1.54 (0.53–4.54) 0.43
≥ 3 h/week 11 (35%) 36 (33%) 1.69 (0.55–5.22) 0.36
Physical activity (strenuous) d 31 109
< 1 h/week (reference) 17 (55%) 66 (61%)
≥ 1 h/week 14 (45%) 43 (39%) 1.23 (0.54–2.80) 0.62
Smoking 31 109
Never (reference) 13 (42%) 42 (39%)
Former 14 (45%) 46 (42%) 0.90 (0.36–2.24) 0.83
Current 4 (13%) 21 (19%) 0.78 (0.21–2.83) 0.70
Previous or present co-morbidity
Hypertension 10 (32%) 31 36 (33%) 109 0.65 (0.25–1.70) 0.38
Diabetes mellitus 9 (29%) 31 17 (16%) 109 1.98 (0.74–5.32) 0.18
Hypothyroidism 6 (19%) 31 12 (11%) 109 1.89 (0.62–5.74) 0.26
Irritable Bowel Syndrome 8 (27%) 30 27 (26%) 105 1.25 (0.47–3.28) 0.66
Mental distress (HSCL-10 score > 1.85) 12 (39%) 31 22 (20%) 109 2.53 (1.04–6.17) 0.04 *
aData are expressed as mean (SD), median (min-max) and n (%)
bBased on logistic regression with ASCA IgG dichotomized at cut-off 10 as the dependent variable and age, gender, BMI and one by one of the column variables
as independent variables
cAdjusted for age and gender only
dCategories are collapsed as compared to originally four categories; no significant differences between the groups were seen when all original categories were
included (data not shown)
*Statistically significant P < 0.05
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ity and immunoglobulin levels [20–22], including a
study which reported concomitant elevations of anti-
food IgG and CRP in obese compared to normal weight
juveniles [22]. This relates to our finding that ASCA IgG-positivity, CRP and body fat mass were all inter-
correlated. Together with a study which showed that IgG
directed against specific enteric bacterial antigens may be
related to obesity and the associated metabolic inflamma-
tion [6], these results indicate that certain dietary or other
Table 3 Biochemical data; comparing ASCA IgG ≥ 10 U/mL to IgG < 10 U/mL a
IgG ≥ 10 U/mL n IgG < 10 U/mL n Adjusted for age, gender
and BMI b
P-value
Odds Ratio (95% CI)
S-CRP, mg/L 7.0 (0–43.0) 31 5.0 (1.0–28.0) 109 1.07 (1.00–1.14) 0.04 *
S-Zonulin, ng/ml 64.1 (17.4–117) 31 52.4 (20.1–186) 105 1.00 (0.99–1.01) 0.89
S-Zonulin ≥48 ng/ml 24 (77%) 31 66 (63%) 105 2.51 (0.95–6.66) 0.06
S-Glucose, mmol/L 5.9 (4.6–23.2) 31 5.6 (4.0–21.5) 109 1.06 (0.94–1.20) 0.31
S-HBA1C, % 5.6 (4.7–11.5) 31 5.4 (4.5–11.1) 109 1.26 (0.96–1.67) 0.10
S-Cholesterol, mmol/L 5.1 (0.9) 31 5.1 (1.0) 109 0.99 (0.64–1.54) 0.97
S-HDL, mmol/L 1.1 (0.7–2.0) 31 1.1 (0.4–2.2) 109 0.53 (0.13–2.18) 0.38
S-LDL, mmol/L 3.3 (0.9) 31 3.4 (0.8) 109 0.97 (0.60–1.57) 0.90
S-Albumin g/L 45.0 (39.0–52.0) 31 44.0 (39.0–52.0) 109 1.20 (1.02–1.42) 0.03 *
S-Total protein, g/L 72.9 (3.2) 31 71.2 (3.8) 109 1.13 (1.01–1.28) 0.04 *
B-MCV, fL 87.3 (4.8) 31 89.2 (4.2) 109 0.87 (0.78–0.96) <0.01 *
B-MCH, pg 29.0 (26.0–34.0) 31 31.0 (25.0–35.0) 109 0.72 (0.56–0.92) 0.01 *
B-Hemoglobin, g/dL 14.6 (1.2) 31 14.4 (1.0) 109 1.23 (0.77–1.96) 0.39
S-Ferritin, μg/L 94.0 (17.0–466) 31 99.0 (7.0–584) 109 1.00 (0.99–1.00) 0.78
aData are expressed as mean (SD), median (min-max) and n (%)
bBased on logistic regression with ASCA IgG dichotomized at cut-off 10 as the dependent variable and age, gender, BMI and one by one of the column variables
as independent variables
*Statistically significant P < 0.05
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ized inflammation commonly seen with increased adipos-
ity. In contrast to our finding, Salamati et al. [1] did not
demonstrate a correlation between serum CRP and ASCA
values. The higher sample size in our study and some dif-
ferences in inclusion criteria may have accounted for this
difference. A limitation is that neither we, nor the study
by Salamati et al. [1], measured other inflammation
markers in addition to CRP. Adipose tissue has many
endocrine functions and a large range of signaling mole-
cules may be released either from the adipose tissue and/
or immune cells within the adipose tissue, implying that
other inflammation markers could be the ones that are
mechanistically linked to ASCA IgG.
Evidence suggests an association between increased gut
permeability and systemic inflammation in obesity, and
the association may be bi-directional [5]. Moreover, high
concentrations of ASCA have been found in Crohn’s dis-
ease [23, 24] and other diseases associated with increased
gut permeability, such as celiac disease and type 1 diabetes
mellitus [25–27]. A “leaky gut”, with increased transloca-
tion of Saccharomyces cerevisiae (or related antigens)
could thus be one potential explanation for the increased
ASCA IgG concentrations and their association with CRP.
In the present study we measured zonulin, a marker of
tight junction permeability in the gut [26]. We found that
elevated zonulin levels were more frequent in subjects
with ASCA IgG-positivity than in subjects negative for
ASCA IgG and the elevated levels correlated significantly
with increasing concentrations of CRP. However, theobserved difference in zonulin between the ASCA IgG-
positive and the ASCA IgG-negative group did not reach
statistical significance. A study of patients with Crohn’s
disease also showed a non-significant trend between ele-
vated ASCA IgG and intestinal permeability, but similar
to our study, could not demonstrate a clear cut association
[23]. Thus it appears that the elevated ASCA concentra-
tions cannot be explained solely by an increased antigenic
challenge due to a leaky gut. Genetic pre-disposition, devi-
ations in the gut microbiota and cross-reactivity of ASCA
with other antigens could be other causes for the raised
ASCA IgG concentrations and their association with body
fat mass and/or inflammation in a sub-group of obese
subjects. These aspects were not explored in the present
study, but could be directions for future research.
Strenghts and limitations
Strength of the study is that it was based on a well
characterized population with the assessment of a wide
range of demographic, clinical and biochemical data,
thereby reducing the risk of unknown confounders. A
limitation is that the many variables that have been
addressed also increased the risk of a type I statistical
error. Information about the use of medications was
however incomplete. Thus, we cannot rule out that
the use of certain drugs could have influenced our
findings. Information regarding certain autoimmune
conditions was also lacking. In the present study, the
95% CI for the proportion of IgG positive samples
ranged between 16% and 30%, which is comparable to
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autoimmune origin, such as type 1 diabetes mellitus
[27], systemic lupus erythematosus [28] and micro-
scopic colitis [29], but lower than in Crohn’s disease
[30]. No significant association was however detected
between ASCA and disorders such as hypothyroidism
or diabetes (the majority of the diabetic patients had
type II diabetes). Moreover, patients with organic
gastrointestinal disorders or former major gastrointes-
tinal surgery were excluded from the study.
The lack of a normal weight control group represents
a limitation with respect to reference values for ASCA,
but based on the aforementioned studies [27–30], the
frequency of IgG positivity in our study was higher than
what would be expected in healthy control subjects, in
whom the reported prevalence ranged between 0 and
5.0% [27–30]. This is also in accordance with the previ-
ous publication of ASCA and obesity by Salamati et al.,
in which none of the normal weight controls were
ASCA positive [1].
Other methodological considerations of the present
study include the dietary assessment tool and our def-
inition of yeast intake: Firstly, calculation of the exact
intake of this yeast was not possible based on our
FFQ. We therefore chose to focus on two major diet-
ary sources of Saccharomyces cerevisiae, namely
bread, buns and other baked goods (baker’s yeast)
and beer (brewer’s yeast). Results from our study did
however not reveal any significant associations be-
tween ASCA and other food groups or between
ASCA and total alcohol consumption. Secondly, be-
cause the FFQ that we applied was designed to study
the habitual diet during the last year, conclusions can-
not be made regarding the impact of more recent diet
or diet early in life. Also, recalling food intake over a
year may be inaccurate, but with respect to the main
dietary sources of yeast, we believe that significant
fluctuations in intake during the year were unlikely.
This is because bread is regarded a staple food in
Norway that is regularly consumed all year round.
Beer on the other hand probably contributes less to
the total intake of yeast as compared to bread.
Conclusions
The findings indicate that ASCA IgG-positivity, which
was detected in a substantial proportion of obese sub-
jects and was associated with body fat mass, may be
linked to the generalized inflammation commonly seen
with increased adiposity. The study did not show an as-
sociation between the habitual intake of food containing
baker’s/brewer’s yeast and either body fat mass or
ASCA, weakening the hypothesis that dietary yeast is
causally related to obesity. The impact of more recent
diet or diet early in life, genetic susceptibility, gutmicrobial composition and cross-reactivity of ASCA
with other antigens were not addressed in the present
study and could be directions for future research. The
finding of a borderline association between ASCA IgG
and intestinal permeability also needs further elucidation.
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